BeiGene, Ltd. (NASDAQ:BGNE) Director Bros. Advisors Lp Baker Sells 1,037,017 Shares

BeiGene, Ltd. (NASDAQ:BGNE) Director Bros. Advisors Lp Baker sold 1,037,017 shares of BeiGene stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $187.27, for a total value of $194,202,173.59. Following the completion of the sale, the director now owns 791,493 shares of the company’s stock, valued at $148,222,894.11. This trade represents a 56.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BeiGene Stock Down 9.7 %

BGNE stock traded down $20.12 during mid-day trading on Tuesday, hitting $187.50. 1,260,565 shares of the company were exchanged, compared to its average volume of 280,145. The firm has a fifty day simple moving average of $210.61 and a 200 day simple moving average of $186.53. The company has a market capitalization of $18.27 billion, a PE ratio of -22.75 and a beta of 0.57. BeiGene, Ltd. has a twelve month low of $126.97 and a twelve month high of $248.16. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.01 EPS. On average, research analysts forecast that BeiGene, Ltd. will post -5.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on BGNE shares. JMP Securities began coverage on shares of BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price on the stock. StockNews.com cut shares of BeiGene from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Morgan Stanley restated an “overweight” rating and issued a $300.00 price objective on shares of BeiGene in a report on Tuesday, December 3rd. TD Cowen lifted their target price on shares of BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. upped their price target on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, October 22nd. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.69.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in BGNE. Blue Trust Inc. raised its stake in BeiGene by 156.3% during the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after acquiring an additional 75 shares during the period. Raymond James & Associates grew its holdings in shares of BeiGene by 0.4% during the second quarter. Raymond James & Associates now owns 21,275 shares of the company’s stock valued at $3,035,000 after purchasing an additional 76 shares during the last quarter. Truist Financial Corp raised its position in shares of BeiGene by 10.1% during the 2nd quarter. Truist Financial Corp now owns 1,521 shares of the company’s stock worth $217,000 after purchasing an additional 140 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in shares of BeiGene in the 3rd quarter worth approximately $36,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in BeiGene by 0.3% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 97,895 shares of the company’s stock valued at $21,978,000 after purchasing an additional 266 shares during the period. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.